Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways. Regorafenib was the first agent to positively show significant survival advantage as a second-line therapy in patients with unresectable hepatocellular carcinoma (HCC) who had previously failed first-line treatment with sorafenib. Recent evidence has shown that its antitumor efficacy is due to a comprehensive spectrum of tumor neo-angiogenesis and proliferation inhibition and immunomodulatory effects on the tumor microenvironment, which plays a crucial role in tumor development. This review addresses the rationale and supporting evidence for regorafenib’s efficacy in HCC that led to regorafenib’s approval as a second-line therapy. In addition, we review proof from clinical practice studies that validate the RESORCE trial results. We discuss regorafenib’s potential role in the newly emerging therapeutic strategy based on combination with immune checkpoint blockade and its possible extensibility to patient categories not enrolled in the registrative study.

Experience with regorafenib in the treatment of hepatocellular carcinoma / Granito A.; Forgione A.; Marinelli S.; Renzulli M.; Ielasi L.; Sansone V.; Benevento F.; Piscaglia F.; Tovoli F.. - In: THERAPEUTIC ADVANCES IN GASTROENTEROLOGY. - ISSN 1756-283X. - STAMPA. - 14:(2021), pp. 1-19. [10.1177/17562848211016959]

Experience with regorafenib in the treatment of hepatocellular carcinoma

Granito A.
;
Forgione A.;Marinelli S.;Renzulli M.;Ielasi L.;Sansone V.;Benevento F.;Piscaglia F.;Tovoli F.
2021

Abstract

Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways. Regorafenib was the first agent to positively show significant survival advantage as a second-line therapy in patients with unresectable hepatocellular carcinoma (HCC) who had previously failed first-line treatment with sorafenib. Recent evidence has shown that its antitumor efficacy is due to a comprehensive spectrum of tumor neo-angiogenesis and proliferation inhibition and immunomodulatory effects on the tumor microenvironment, which plays a crucial role in tumor development. This review addresses the rationale and supporting evidence for regorafenib’s efficacy in HCC that led to regorafenib’s approval as a second-line therapy. In addition, we review proof from clinical practice studies that validate the RESORCE trial results. We discuss regorafenib’s potential role in the newly emerging therapeutic strategy based on combination with immune checkpoint blockade and its possible extensibility to patient categories not enrolled in the registrative study.
2021
Experience with regorafenib in the treatment of hepatocellular carcinoma / Granito A.; Forgione A.; Marinelli S.; Renzulli M.; Ielasi L.; Sansone V.; Benevento F.; Piscaglia F.; Tovoli F.. - In: THERAPEUTIC ADVANCES IN GASTROENTEROLOGY. - ISSN 1756-283X. - STAMPA. - 14:(2021), pp. 1-19. [10.1177/17562848211016959]
Granito A.; Forgione A.; Marinelli S.; Renzulli M.; Ielasi L.; Sansone V.; Benevento F.; Piscaglia F.; Tovoli F.
File in questo prodotto:
File Dimensione Formato  
Granito 2021 Regorafenib.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione 996.14 kB
Formato Adobe PDF
996.14 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/853908
Citazioni
  • ???jsp.display-item.citation.pmc??? 60
  • Scopus 79
  • ???jsp.display-item.citation.isi??? 79
social impact